Preloader

EndoPredict® is a second-generation 12 gene molecular assay designed for patients with early-stage (Stage I–III), ER-positive/HER2-negative breast cancer. It predicts the risk of distant recurrence and helps assess the potential benefit of adjuvant chemotherapy.

Genomic data generated by the test are combined with clinical parameters, including tumor size and lymph node status, to calculate the EPclin® score.

Endopredict

EndoPredict:

  • Combines genomic information with clinicopathological factors to accurately stratify patients into low- and high-risk groups.
  • Only genomic test that predicts the risk of distant recurrence for up to 15 years.
  • Helps estimate the potential benefit of adjuvant chemotherapy over a 10-year period.
  • Included in major international clinical guidelines, including ASCO, NCCN, AJCC, ESMO, St. Gallen, and NICE.

 

FeatureDetails
Cancer TypeEarly-Stage Breast Cancer (ER+, HER2−)
Recommended For
  • ER positive, HER2 negative tumors
  • Lymph node-negative or lymph node-positive disease
  • Stage I–III (T1–T3) disease
  • Premenopausal and postmenopausal patients
Sample TypeTumor Tissue (FFPE)
MethodReal-Time qPCR
Genomic Signature12-Gene Molecular Score (EPclin®)
Turnaround Time2–3 Weeks
//
Our customer support team is here to answer your questions!